Amgen unties BIND as nanomedicine collaboration fails
This article was originally published in Scrip
Executive Summary
Amgen and BIND Therapeutics have ended their collaboration to develop a nanomedicine for treating solid cancer tumors owing to unsatisfactory results from early investigations.